The Wegovy pill saw the fastest take-up in weight-loss drug history. Novo Nordisk only narrowly lifted guidance.
06.05.26 09:25 Uhr
Werbung
Werte in diesem Artikel
Indizes
PKT PKT
1.481,3 PKT -8,1 PKT -0,54%
1.230,6 PKT -5,5 PKT -0,44%
2.594,3 PKT -42,0 PKT -1,59%
5.156,1 PKT -24,7 PKT -0,48%
Novo Nordisk on Wednesday narrowly improved its financial guidance for a year where it still sees profit and sales falling after the fastest take-up in weight-loss drug history for its Wegovy pill.Weiter zum vollständigen Artikel bei MarketWatch
Quelle: MarketWatch
